چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| حامد ابراهیم زاده لیل آبادلو | اول |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Fecal Microbiota Transplantation، Liver Disorders، Gut microbiota |
| خلاصه مقاله | Introduction: The human gut hosts a diverse microbial community essential for health. Dysbiosis is linked to acute and chronic liver diseases, including fatty liver, cirrhosis, and autoimmune liver disorders. Fecal microbiota transplantation (FMT) has emerged as a promising approach to restore microbial balance and support liver function. Materials and Methods: A literature review of studies published between 2015 and 2025 was conducted using PubMed, Scopus, and Web of Science. Keywords included: 'fecal microbiota transplantation,' 'gut microbiome,' 'liver disease,' 'dysbiosis,' 'fatty liver,' 'cirrhosis,' and 'autoimmune liver disease.' Relevant basic science and clinical studies were selected. Results: Evidence from animal models and clinical studies indicates that FMT can restore gut microbial diversity and correct dysbiosis. Patients undergoing FMT showed improved liver function tests, reduced inflammation, and enhanced overall metabolic profiles. The intervention was generally safe and well-tolerated. Conclusion: FMT is a promising therapeutic strategy for acute and chronic liver diseases by rebuilding a healthy gut microbiome. Clinical evidence suggests it can improve liver function, reduce inflammation, and support faster recovery, making it a valuable adjunct or alternative to conventional treatments. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| certificate-1.pdf | 1404/10/07 | 130213 | دانلود |
| Fecal Microbiota Transplantation as a Therapeutic Strategy in Liver Disorders.jpg | 1404/10/14 | 638568 | دانلود |
